Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient.
1. A method for preventing cervical or vaginal cancer in patients with dysplasia comprising the steps of
(a) identifying a dysplasia (CIN/VIN) patient,
(b) administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce dysplasia and prevent cervical cancer; and
(c) measuring a reduction of dysplasia and absence or slowing of progression to cervical/vaginal cancer.
2. The method of claim 1 wherein the estrogen antagonist is selected from fulvestrant and raloxifene.
3. The method of claim 1 wherein the estrogen antagonist is a selective estrogen receptor modulator with antagonistic effects in the cervix/vagina.